Table 2 Cox regression analysis of TEDC2 and clinicopathologic characteristics with survival outcomes in LUAD.

From: TEDC2 correlated with prognosis and immune microenvironment in lung adenocarcinoma

Characteristics

Univariate analysis

Multivariate analysis

HR

95% CI

P

HR

95% CI

P

Overall survival

 Age (> 65 vs. ≤ 65)

1.223

0.916–1.635

0.172

   

 Gender (Male vs. Female)

1.070

0.803–1.426

0.642

   

 Smoking history (Yes vs. No)

0.894

0.592–1.348

0.591

   

 T stage (T2 & T3 & T4 vs. T1)

1.728

1.229–2.431

0.002

1.615

1.032–2.529

0.036

 N stage (N1 & N2 & N3 vs. N0)

2.601

1.944–3.480

 < 0.001

1.714

0.957–3.070

0.070

 M stage (M1 vs. M0)

2.136

1.248–3.653

0.006

1.512

0.818–2.794

0.188

 Pathologic stage (Stage II & Stage III & Stage IV vs. Stage I)

2.933

2.173–3.958

 < 0.001

1.414

0.757–2.643

0.277

 TEDC2 (High vs. Low)

1.704

1.273–2.282

 < 0.001

1.498

1.057–2.124

0.023

Disease specific survival

 Age (> 65 vs. ≤ 65)

1.013

0.701–1.464

0.944

   

 Gender (Male vs. Female)

0.989

0.687–1.424

0.954

   

 Smoking history (Yes vs. No)

1.040

0.602–1.796

0.889

   

 T stage (T2 & T3 & T4 vs. T1)

1.850

1.195–2.865

0.006

1.582

0.894–2.801

0.115

 N stage (N1 & N2 & N3 vs. N0)

2.703

1.873–3.900

 < 0.001

1.707

0.819–3.556

0.153

 M stage (M1 vs. M0)

2.455

1.269–4.749

0.008

1.864

0.870–3.995

0.109

 Pathologic stage (Stage II & Stage III & Stage IV vs. Stage I)

3.291

2.237–4.842

 < 0.001

1.338

0.602–2.974

0.476

 TEDC2 (High vs. Low)

1.796

1.240–2.601

0.002

1.774

1.120–2.810

0.015

Progress free survival

 Age (> 65 vs. ≤ 65)

1.023

0.784–1.335

0.867

   

 Gender (Male vs. Female)

1.172

0.901–1.526

0.236

   

 Smoking history (Yes vs. No)

0.968

0.658–1.426

0.870

   

 T stage (T2 & T3 & T4 vs. T1)

1.882

1.379–2.570

 < 0.001

1.519

1.098–2.101

0.012

 N stage (N1 & N2 & N3 vs. N0)

1.512

1.152–1.984

0.003

0.833

0.549–1.262

0.388

 M stage (M1 vs. M0)

1.513

0.855–2.676

0.155

   

 Pathologic stage (Stage II & Stage III & Stage IV vs. Stage I)

1.960

1.502–2.557

 < 0.001

1.836

1.210–2.784

0.004

 TEDC2 (High vs. Low)

1.422

1.092–1.851

0.009

1.243

0.945–1.633

0.119

Back to article page